Recent progress in stimuli‐activable metallo‐prodrugs for cancer therapy
Abstract The clinical approval of platinum‐based drugs has prompted the development of novel metallo‐complexes during the last several decades, while severe problems, especially for poor water solubility, drug resistance and toxicity in patients, greatly hindered the clinical trials and curative eff...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-09-01
|
| Series: | Smart Molecules |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/smo.20240030 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849221262924054528 |
|---|---|
| author | Jinzhe Liang Fangmian Wei Hui Chao |
| author_facet | Jinzhe Liang Fangmian Wei Hui Chao |
| author_sort | Jinzhe Liang |
| collection | DOAJ |
| description | Abstract The clinical approval of platinum‐based drugs has prompted the development of novel metallo‐complexes during the last several decades, while severe problems, especially for poor water solubility, drug resistance and toxicity in patients, greatly hindered the clinical trials and curative efficacy. To address these issues, the concept of metallo‐prodrugs has been proposed for oncology. Some stimuli‐activable metallo‐prodrugs provide new insights for designing and preparing site‐specific prodrugs with maximized therapeutic efficacy and negligible unfavorable by‐effects. In this review, recent progress in stimuli‐activable metallo‐prodrugs in the past 20 years has been overviewed, where endogenous and exogenous stimuli have been involved. Typical examples of smart stimuli‐activable metallo‐prodrugs are discussed regarding to their molecular structure, activation mechanism, and promising biomedical applications. In the end, challenges and future perspectives in metallo‐prodrugs have been discussed. |
| format | Article |
| id | doaj-art-e37ab58d6c554ecfbbcd5aef72867c36 |
| institution | Kabale University |
| issn | 2751-4587 2751-4595 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | Smart Molecules |
| spelling | doaj-art-e37ab58d6c554ecfbbcd5aef72867c362024-11-17T09:40:28ZengWileySmart Molecules2751-45872751-45952024-09-0123n/an/a10.1002/smo.20240030Recent progress in stimuli‐activable metallo‐prodrugs for cancer therapyJinzhe Liang0Fangmian Wei1Hui Chao2MOE Key Laboratory of Bioinorganic and Synthetic Chemistry Guangdong Basic Research Center of Excellence for Functional Molecular Engineering School of Chemistry Sun Yat‐Sen University Guangzhou ChinaState Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources MOE Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources Collaborative Innovation Center for Guangxi Ethnic Medicine School of Chemistry and Pharmaceutical Sciences Guangxi Normal University Guilin ChinaMOE Key Laboratory of Bioinorganic and Synthetic Chemistry Guangdong Basic Research Center of Excellence for Functional Molecular Engineering School of Chemistry Sun Yat‐Sen University Guangzhou ChinaAbstract The clinical approval of platinum‐based drugs has prompted the development of novel metallo‐complexes during the last several decades, while severe problems, especially for poor water solubility, drug resistance and toxicity in patients, greatly hindered the clinical trials and curative efficacy. To address these issues, the concept of metallo‐prodrugs has been proposed for oncology. Some stimuli‐activable metallo‐prodrugs provide new insights for designing and preparing site‐specific prodrugs with maximized therapeutic efficacy and negligible unfavorable by‐effects. In this review, recent progress in stimuli‐activable metallo‐prodrugs in the past 20 years has been overviewed, where endogenous and exogenous stimuli have been involved. Typical examples of smart stimuli‐activable metallo‐prodrugs are discussed regarding to their molecular structure, activation mechanism, and promising biomedical applications. In the end, challenges and future perspectives in metallo‐prodrugs have been discussed.https://doi.org/10.1002/smo.20240030cancer therapymetallo‐prodrugsstimuli‐activable |
| spellingShingle | Jinzhe Liang Fangmian Wei Hui Chao Recent progress in stimuli‐activable metallo‐prodrugs for cancer therapy Smart Molecules cancer therapy metallo‐prodrugs stimuli‐activable |
| title | Recent progress in stimuli‐activable metallo‐prodrugs for cancer therapy |
| title_full | Recent progress in stimuli‐activable metallo‐prodrugs for cancer therapy |
| title_fullStr | Recent progress in stimuli‐activable metallo‐prodrugs for cancer therapy |
| title_full_unstemmed | Recent progress in stimuli‐activable metallo‐prodrugs for cancer therapy |
| title_short | Recent progress in stimuli‐activable metallo‐prodrugs for cancer therapy |
| title_sort | recent progress in stimuli activable metallo prodrugs for cancer therapy |
| topic | cancer therapy metallo‐prodrugs stimuli‐activable |
| url | https://doi.org/10.1002/smo.20240030 |
| work_keys_str_mv | AT jinzheliang recentprogressinstimuliactivablemetalloprodrugsforcancertherapy AT fangmianwei recentprogressinstimuliactivablemetalloprodrugsforcancertherapy AT huichao recentprogressinstimuliactivablemetalloprodrugsforcancertherapy |